Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Net Cash Flow (2021 - 2025)

Senti Biosciences has reported Net Cash Flow over the past 5 years, most recently at $4.2 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $4.2 million for Q4 2025, down 88.97% from a year ago — trailing twelve months through Dec 2025 was -$31.9 million (down 357.68% YoY), and the annual figure for FY2025 was -$31.9 million, down 357.68%.
  • Net Cash Flow for Q4 2025 was $4.2 million at Senti Biosciences, up from -$9.3 million in the prior quarter.
  • Over the last five years, Net Cash Flow for SNTI hit a ceiling of $101.7 million in Q2 2022 and a floor of -$57.2 million in Q4 2022.
  • Median Net Cash Flow over the past 5 years was -$6.4 million (2023), compared with a mean of -$1.9 million.
  • Peak annual rise in Net Cash Flow hit 9167.98% in 2022, while the deepest fall reached 6537.26% in 2022.
  • Senti Biosciences' Net Cash Flow stood at $889323.0 in 2021, then tumbled by 6537.26% to -$57.2 million in 2022, then skyrocketed by 88.86% to -$6.4 million in 2023, then soared by 692.08% to $37.8 million in 2024, then plummeted by 88.97% to $4.2 million in 2025.
  • The last three reported values for Net Cash Flow were $4.2 million (Q4 2025), -$9.3 million (Q3 2025), and -$12.2 million (Q2 2025) per Business Quant data.